These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17635825)

  • 21. Hyperphosphatemia among end-stage renal disease patients in developing countries: a forgotten issue?
    Afifi A; El-Sayed H; El-Setouhi M; Ahmed H; Khalifa N
    Hemodial Int; 2005 Oct; 9(4):409-15. PubMed ID: 16219062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment.
    Kestenbaum B
    Semin Dial; 2007; 20(4):286-94. PubMed ID: 17635817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical approaches to management of hyperphosphatemia: can we improve the current situation?
    Kuhlmann MK
    Blood Purif; 2007; 25(1):120-4. PubMed ID: 17170549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
    Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
    J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lanthanum carbonate--a first line phosphate binder?
    de Freitas D; Donne RL; Hutchison AJ
    Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dietitian-led education program to improve phosphate control in a single-center hemodialysis population.
    Reddy V; Symes F; Sethi N; Scally AJ; Scott J; Mumtaz R; Stoves J
    J Ren Nutr; 2009 Jul; 19(4):314-20. PubMed ID: 19539185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia.
    Savica V; Calò LA; Caldarera R; Cavaleri A; Granata A; Santoro D; Savica R; Muraca U; Mallamace A; Bellinghieri G
    Nephron Physiol; 2007; 105(3):p52-5. PubMed ID: 17220638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of hyperphosphatemia.
    Kuhlmann MK
    Hemodial Int; 2006 Oct; 10(4):338-45. PubMed ID: 17014508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The case against calcium-based phosphate binders.
    Moe SM; Chertow GM
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):697-703. PubMed ID: 17699275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there increasing evidence to change the management of renal bone disease?
    Harum P
    Nephrol News Issues; 1999 Apr; 13(4):55-6. PubMed ID: 10418451
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical effect of introduction of sevelamer hydrochloride in patients with hyperphosphatemia undergoing maintenance dialysis].
    Tahara H; Tsujimoto Y; Shouji T; Inaba M; Tabata T; Nishizawa Y
    Clin Calcium; 2005 Sep; 15 Suppl 1():173-9. PubMed ID: 16279021
    [No Abstract]   [Full Text] [Related]  

  • 32. Phosphate management in chronic kidney disease.
    Bhan I
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):174-9. PubMed ID: 24445424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acute hyperphosphatemia secondary to phosphate administration for bowel preparation].
    Gutiérrez E; González E; Hernández E; Herrero JC; Manzanera MJ; García JA; Domínguez-Gil B; Praga M
    Nefrologia; 2004; 24(3):283-7. PubMed ID: 15283320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of hyperphosphatemia in hemodialysis patients].
    Rieu P
    Nephrol Ther; 2005 Dec; 1 Suppl 4():S322-9. PubMed ID: 17373203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low prevalence of hyperphosphatemia independent of residual renal function in peritoneal dialysis patients.
    Dong J; Wang H; Wang M
    J Ren Nutr; 2007 Nov; 17(6):389-96. PubMed ID: 17971311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new era in phosphate binder therapy: what are the options?
    Salusky IB
    Kidney Int Suppl; 2006 Dec; (105):S10-5. PubMed ID: 17136110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The continuous challenge of cardiovascular and bone and bone disease in uremic patients: clinical consequences of hyperphosphatemia and advanced therapeutic approaches.
    Brancaccio D; Zoccali C
    J Nephrol; 2006; 19(1):12-20. PubMed ID: 16523420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review.
    Sigrist MK; Chiarelli G; Lim L; Levin A
    J Ren Care; 2009 Mar; 35 Suppl 1():71-8. PubMed ID: 19222735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salivary phosphate secretion in chronic kidney disease.
    Savica V; Calò L; Santoro D; Monardo P; Granata A; Bellinghieri G
    J Ren Nutr; 2008 Jan; 18(1):87-90. PubMed ID: 18089451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel iron-based phosphate binders in patients with chronic kidney disease.
    Shah HH; Hazzan AD; Fishbane S
    Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):330-5. PubMed ID: 26050119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.